# Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus

> **NCT05057481** · PHASE3 · UNKNOWN · sponsor: **Assiut University** · enrollment: 30 (estimated)

## Conditions studied

- Autoimmune Hemolytic Anemia
- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Mycophenolate Mofetil 500mg
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT05057481
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-15
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-01-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05057481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05057481, "Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT05057481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*